Search

everythinglearnresearchcommunity

for

Search:↓

Certain factors like patchy hair loss at the back of the head, being female, and younger age at diagnosis can lead to a worse outcome for alopecia areata.

Azathioprine is the most continued treatment for chronic alopecia areata over a year, often with added low-dose prednisolone.

Baricitinib treatment helps regrow eyebrow, eyelash, and scalp hair in severe alopecia areata, improving patients' emotional well-being and quality of life.

Patients with severe alopecia areata felt better and less anxious or depressed when treated with baricitinib compared to placebo.

Early onset, severe types, nail changes, family history, and body hair loss worsen alopecia areata prognosis; sticking to treatment helps.

Continuous treatment with ritlecitinib and brepocitinib is needed to maintain hair regrowth in alopecia areata.

Yellow dots are common in severe alopecia areata.

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

Tofacitinib can regrow hair in alopecia areata patients, but some may experience flares during treatment.

Some people developed alopecia areata after COVID-19 vaccination, but it's not caused by the vaccine and most improved with treatment.

CAR is a useful marker for assessing alopecia areata severity.

Janus kinase inhibitors can regrow hair in alopecia areata but may cause side effects and hair loss may return if treatment stops.

Both azathioprine and betamethasone treatments effectively regrow hair in alopecia areata, but azathioprine may be safer.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.

PRP is more effective than Minoxidil for treating alopecia areata.

Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.

Sequential therapy with dupilumab and baricitinib improved hair regrowth and atopic dermatitis in a child without adverse reactions.

Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.

There's no strong link between Alopecia Areata, a hair loss condition, and fatty liver, but more research is needed.

Children with alopecia areata often have low vitamin D, especially if they have darker skin, it's not summer, or they're not White.

Standard intralesional corticosteroids are the best treatment for patchy alopecia areata.

Both azathioprine and betamethasone treatments help with hair regrowth in alopecia areata, but azathioprine may have fewer side effects.

Betamethasone is more effective for hair regrowth than latanoprost but has more side effects.

Combining platelet-rich plasma and minoxidil can effectively regrow hair in severe alopecia areata cases.

Alopecia areata causes hair loss and life quality issues; current treatments are often unsatisfactory, but new drugs like JAK inhibitors show promise.

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.